- Second case following c-myc inhibitor ‘ICX-101’ currently in pre-clinical trial

Incurix announced today that the company in-licensed the STAT3 inhibitor anti-cancer substance from the National Cancer Center (NCC) and the Korea Research Institute of Chemical Technology (KRICT). The agreement is the second after last year’s in-licensing of the c-myc inhibitor. Company officials explained that securing another pipeline of new transcription factor inhibitor is meaningful, following the c-myc inhibitor ‘ICX-101,’ currently in pre-clinical studies. As a transcription factor that controls cell development, survival and immune function, STAT3 is known to be over-expressed in several cancers, causing tumor formation and metastasis. The direct inhibitor of STAT3 is yet to be developed.

“Through Incurix’s differentiated new drug development know-hows and system, we will succeed in developing an additional transcription factor targeting anti-cancer drug that we in-licensed,” Incurix CEO Kyung-chae Jeong said. Meanwhile, Incurix was founded by NCC Senior Director Dr. Kyung-Chae Jeong. The newly licensed compound is a new target anti-cancer substance that Dr. Jeong co-developed with Hwan-jung Lim, Head of New Drug Pipeline Research at KRICT, and Senior Researcher Sung-joon Park.

http://www.biospectator.com/view/news_view.php?varAtcId=13560